• PROGENICS PHARMACEUTICALS IN Financial Overview

  • Income Statement: PGNX

      2007 2006 Change ( 2006 - 2007  )
    Net Sales/Revenues 75.65 M 69.91 M 5.74 M 7.59%
    Gross Profit 72.62 M 7.74 M 64.88 M 89.34%
    Net Income Before Extra Items/Preferred Div -43.69 M -21.62 M -22.07 M 50.52%
    Operating Income -51.46 M -15.99 M -35.47 M 68.93%
  • Cash Flow: PGNX

      2007 2006 Change ( 2006 - 2007  )
    Net Cash Flow - Financing 64.88 M 7.08 M 57.81 M 89.10%
    Net Cash Flow - Investing 27.36 M 53.04 M -25.69 M -93.89%
    Net Cash Flow/Operating Activities -39.05 M -9.16 M -29.89 M 76.55%
  • Balance Sheet: PGNX

      2007 2006 Change ( 2006 - 2007  )
    Total Assets 189.54 M 165.91 M 23.63 M 12.47%
    Total Liabilities 42.04 M 55.06 M -13.02 M -30.98%
    Shareholders Equity 147.50 M 110.85 M 36.65 M 24.85%
  • Key Ratios / Statistics: PGNX

    • Valuation

      Price/Earnings (TTM) -11.29
      Price/Sales (TTM) 6.54
      Price/Book (MRQ) 3.44
      Price/Cash Flow (TTM) -13.71
    • Profitability

      Gross Margin 96.00
      Operating Margin -68.02
      Profit Margin -57.75
    • Dividends

      Dividend Paid (TTM) 0.00
      Payout Ratio % (TTM) 0.00
    • Financial Strength

      Quick Ratio (MRQ) 4.07
      Current Ratio (MRQ) 4.42
      Long Term Debt-to-Equity (MRQ) 0.00
    • Management Effectiveness

      Return on Equity (TTM) -34.83
      Return on Assets (TTM) -29.74
      Return on Investments (TTM) -33.82